Financial Disclosures

Transcription

1 Financial Disclosures The PHy EU ongress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of PHy participants. In doing so, the PHy EU ongress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials. Educational ontent Development The PHy EU ongress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content. Presenters The PHy EU ongress considers financial relationships to create actual conflicts of interest when Presenters or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Presenter) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the PHy EU ongress of ME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the ME an incentive to insert commercial bias. All presenters of ME content should familiarize themselves with the policy of the PHy EU ongress of ME based on the ME provider of the ongress the EAME ( ). All PHy Faculty presenting ME are required to disclose to the activity audience the following information prior to beginning their presentation: Any relevant financial relationships a ME presenter has had with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services within the past 12 months. The PHy ongress defines "relevant" financial relationships as those with a commercial ophthalmic interest and the opportunity to affect the content of ME about the products or services of that commercial ophthalmic interest ME presenters who report they have no known relevant financial relationships to disclose will declare "o Financial Relationships" TE: All presenters are required to report financial disclosures, using the codes below. An individual's financial disclosures for the 9 th PHy EU ongress meeting are listed in this ection. PHy Financial Disclosure odes ategory ode Description one onsultant onsultant fee, paid advisory boards Advisor fees for attending a meeting (for the past 1 year) Employee E Employed by a commercial entity ecture fees ecture fees (honoraria), travel fees or reimbursements when peaking at the invitation of a commercial entity (for the past 1 year) Equity owner Equity ownership/stock options or publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services Patents / P Patents and/or royalties that might be viewed as creating a Royalty potential conflict of interest Grant support Grant support for the past 1 year (all sources) and all sources Used for this project if this form is an update for a specific talk or publication with no time limitation

2 Disclosure Information Financial interest disclosures from program members and others in a position for control content: Jorge Alio, pain ofia Androudi, Greece Abbvie ervier XMA Ehud Assia, Israel Visionare Hanita enses BioTechnology General APX phthalmology IPtima VisiDom Miltos Balidis, Greece Irit Bahar, Israel Francesco Bandello, Italy Alimera ciences Bausch & omb Boehringer-Ingelheim Farmila Genentech Hofmann a ovagali Pharma ifi ooft Thrombogenics Zeiss Dalia Berman, Denmark Dimitrios Besinis, Greece Francesco Boscia, Italy Pfenex eil Bressler, UA hair, Genetech/ umenis amsung Bioepis Alkeus hiltern usan Bressler, UA otel Vision td Boehringher Ingelheim Genetech IH Jaeb Daniel Briscoe, Israel telios haidoulis, Greece Alexandros haronis, Greece, Faculty Memeber George haronis, Greece Irini hatziralli, Greece Boehringer-Ingelheim Francesca ordeiro, UK ection Head, Faculty Vissufarma Dompe Marc de met, witzerland ightstar Therapeutics Abbvie Preceyes,

3 Bora Eldem, Turkey Pfizer ervier Alimera phtotech Bausch & omb Anastasios Konstas, Greece hryssanthi Koutsandrea, Greece Konstantina Koufala, Greece George Kymonis, Greece Theodoros Filippopoulos, Greece, Faculty Memeber Dimitris Kyroudis, Greece Pedro uis Fonseca, Portugal Ioannis adas, Greece pyros Georgaras, Greece Michaella Goldstein, Israel tratos Gotzaridis, Greece Regional o-hair, Paulo anzetta, Italy entervue Ruth apid-gortzak, The etherlands. Eye Yon DAK Hanita enses Taiho ncology Pharma Zohar Habot-Wilner, Israel Igal eibovitch, Israel Anton Hommer, Austria Vasilis iarakos, Greece tamatina Kabanarou, Greece tephan Kaminski, Austria Anat oewenstein, Israel hair, otal Vision Forsight Vikentia Katsanevaki, Greece Panagiotis Malamos, Greece

4 George Mangouritsas, Greece William Meiler, UA eil Miller, UA RDI Quark Pharmaceutical ompany Joseph Moisseiev, Israel Jordi Monés, pain Athanasios ikolakopoulos, Greece Regional o-hair, Thekla Papadaki, Greece Peter mahliou, Greece Panos tavrakas, Greece James Talks, UK ptos Panagiotis Theodossaiadis, Greece Fotis Topouzis, Greece Valerie Touitou, France Pierre Fabre anthera Pandelis Papadopoulos, Greece Yannis Tountas, Greece Miltos Papathanasiou, Greece Paris Tranos, Greece Efstratios Parikakis, Greece Ioanna Tryfinopoulou, Greece Petros Petrou, Greece Tryfon Rotsos, Greece Miltiadis Tsilimbaris, Greece Mavrogenis A KPER Kostantinos amaras, Greece Dimitris iganos, Greece obha ivaprasad, UK Patricia Udaondo, pain Gene ignal Bausch + omb icox David Varssano, Israel

5 Tina Xirou, Greece